Suppr超能文献

在阿曼,五价轮状病毒疫苗的成本效益。

Cost effectiveness of a pentavalent rotavirus vaccine in Oman.

机构信息

Office of HE of Health Affairs, Ministry of Health, Muscat, Oman.

出版信息

BMC Infect Dis. 2014 Jun 17;14:334. doi: 10.1186/1471-2334-14-334.

Abstract

BACKGROUND

Rotavirus gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring substantial healthcare and economic burden. We propose to formally assess the potential cost effectiveness of implementing universal vaccination with a pentavalent rotavirus vaccine (RV5) on reducing the health care burden and costs associated with rotavirus gastroenteritis (RGE) in Oman

METHODS

A Markov model was used to compare two birth cohorts, including children who were administered the RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first 5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department (ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY) gained from health care system and societal perspectives.

RESULTS

A universal RV5 vaccination program is projected to reduce, hospitalizations, ED visits, outpatient visits and parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, respectively. In the absence of RV5 vaccination, RGE-related societal costs are projected to be 2,023,038 Omani Rial (OMR) (5,259,899 United States dollars [USD]), including 1,338,977 OMR (3,481,340 USD) in direct medical costs. However, with the introduction of RV5, direct medical costs are projected to be 216,646 OMR (563,280 USD). Costs per QALY saved would be 1,140 OMR (2,964 USD) from the health care payer perspective. An RV5 vaccination program would be considered cost saving, from the societal perspective.

CONCLUSIONS

Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective and cost saving from the societal perspective.

摘要

背景

轮状病毒胃肠炎(RGE)是阿曼婴幼儿腹泻的主要原因,给医疗保健系统带来了巨大的经济负担。我们建议正式评估在阿曼实施五价轮状病毒疫苗(RV5)普遍接种的潜在成本效益,以降低轮状病毒胃肠炎(RGE)相关的医疗保健负担和成本。

方法

使用马尔可夫模型比较了两个出生队列,包括接种 RV5 疫苗的儿童和未接种疫苗的儿童,在阿曼 65500 名儿童中,假设他们在 5 岁之前接受了随访。疫苗对减少轮状病毒相关住院、急诊(ED)和门诊就诊以及接种疫苗儿童父母因轮状病毒感染而损失的工作天数的疗效基于轮状病毒疗效和安全性试验(REST)的结果。关注的结果是从医疗保健系统和社会角度计算的每获得一个质量调整生命年(QALY)的成本。

结果

普遍接种 RV5 疫苗方案预计将使轮状病毒感染导致的住院、ED 就诊、门诊就诊和父母因轮状病毒感染而损失的工作天数分别减少 89%、80%、67%和 74%。在没有 RV5 疫苗接种的情况下,预计 RGE 相关的社会成本为 2023038 里亚尔(OMR)(5259899 美元),其中直接医疗费用为 1338977 里亚尔(3481340 美元)。然而,随着 RV5 的引入,预计直接医疗费用将为 216646 里亚尔(563280 美元)。从医疗保健支付者的角度来看,每节省一个 QALY 的成本将为 1140 里亚尔(2964 美元)。从社会角度来看,RV5 疫苗接种计划将被认为是具有成本效益的。

结论

在阿曼普遍接种 RV5 疫苗可能会显著降低轮状病毒胃肠炎相关的医疗保健负担和成本,从支付者的角度来看可能具有成本效益,从社会的角度来看可能具有成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c67e/4078940/4985e3454e9b/1471-2334-14-334-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验